Blue Earth Team

Our Directors come from a wide-range of relevant backgrounds and make an active contribution to company strategy.

Board Members

  • Elisa Petris's photo
    Elisa Petris

    Board Member

    Elisa is a Partner of Syncona Investment Management Ltd. Previously, she was a Senior Associate at Michel Dyens & Co. working on transactions covering the healthcare space, and a member of the Life Science team at L.E.K. Consulting based in London. While at L.E.K. she worked on projects for biotech, pharma and private equity clients.

    Elisa has a PhD in Molecular Biology from Imperial College and an MBA from London Business School.

  • Jonathan Allis's photo
    Jonathan Allis

    Chief Executive Officer

    Jonathan Allis is the founding CEO of Blue Earth Diagnostics. Prior to this role, Jonathan was the General Manager for PET at GE Healthcare Life Sciences, and had global responsibility for GE Healthcare’s PET agent and PET synthesis platforms business. He has previously held positions in R&D, Marketing and Product Development at GE Healthcare, Amersham plc, Siemens Medical Solutions and Oxford Magnet Technology, in the UK, USA and Germany.

    Jonathan is co-chair of the Society of Nuclear Medicine and Molecular Imaging Value Initiative Industry Alliance for 2018 – 2019.

    Jonathan has an undergraduate degree in Physics from the University of Cape Town and a doctorate in Biochemistry from the University of Oxford.

  • Martin Murphy's photo
    Martin Murphy


    Martin is the Chief Executive Officer of Syncona Investment Management Ltd and co-founder of Syncona Partners LLP. Previously, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare investments. During his time at MVM, Martin was a member of the Management and Investment Committees and led MVM’s European operations. He was involved in a number of investments including PregLem SA (sold to Gedeon Richter), Momenta Pharmaceuticals, Inc, (NASDAQ: MNTA), Healthcare Brands International (sold to Meda AB) and Heptares Therapeutics Ltd (sold to Sosei Group Corporation). Before MVM, Martin had roles with 3i Group plc and McKinsey & Company.

    Martin has a PhD in Biochemistry from Cambridge University.